RFX5_HUMAN
ID RFX5_HUMAN Reviewed; 616 AA.
AC P48382; B7Z848; D3DV19; E9PFU4; Q5VWC3;
DT 01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT 01-FEB-1996, sequence version 1.
DT 03-AUG-2022, entry version 185.
DE RecName: Full=DNA-binding protein RFX5;
DE AltName: Full=Regulatory factor X 5;
GN Name=RFX5;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX PubMed=7744245; DOI=10.1101/gad.9.9.1021;
RA Steimle V., Durand B., Barras E., Zufferey M., Hadam M.R., Mach B.,
RA Reith W.;
RT "A novel DNA-binding regulatory factor is mutated in primary MHC class II
RT deficiency (bare lymphocyte syndrome).";
RL Genes Dev. 9:1021-1032(1995).
RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC TISSUE=Testis;
RX PubMed=14702039; DOI=10.1038/ng1285;
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA Isogai T., Sugano S.;
RT "Complete sequencing and characterization of 21,243 full-length human
RT cDNAs.";
RL Nat. Genet. 36:40-45(2004).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=16710414; DOI=10.1038/nature04727;
RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT "The DNA sequence and biological annotation of human chromosome 1.";
RL Nature 441:315-321(2006).
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA Hunkapiller M.W., Myers E.W., Venter J.C.;
RL Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN [5]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC TISSUE=Uterus;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [6]
RP PARTIAL PROTEIN SEQUENCE.
RC TISSUE=Lymphoblast;
RX PubMed=10072068; DOI=10.1016/s1074-7613(00)80016-3;
RA Nagarajan U.M., Louis-Plence P., DeSandro A., Nilsen R., Bushey A.,
RA Boss J.M.;
RT "RFX-B is the gene responsible for the most common cause of the bare
RT lymphocyte syndrome, an MHC class II immunodeficiency.";
RL Immunity 10:153-162(1999).
RN [7]
RP ERRATUM OF PUBMED:10072068.
RA Nagarajan U.M., Louis-Plence P., DeSandro A., Nilsen R., Bushey A.,
RA Boss J.M.;
RL Immunity 10:399-399(1999).
RN [8]
RP CHARACTERIZATION.
RX PubMed=10779326; DOI=10.1128/mcb.20.10.3364-3376.2000;
RA Villard J., Peretti M., Masternak K., Barras E., Caretti G., Mantovani R.,
RA Reith W.;
RT "A functionally essential domain of RFX5 mediates activation of major
RT histocompatibility complex class II promoters by promoting cooperative
RT binding between RFX and NF-Y.";
RL Mol. Cell. Biol. 20:3364-3376(2000).
RN [9]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-185, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma;
RX PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT site occupancy during mitosis.";
RL Sci. Signal. 3:RA3-RA3(2010).
RN [10]
RP ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP [LARGE SCALE ANALYSIS].
RX PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT "N-terminal acetylome analyses and functional insights of the N-terminal
RT acetyltransferase NatB.";
RL Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN [11]
RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10, AND IDENTIFICATION BY
RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Cervix carcinoma, and Erythroleukemia;
RX PubMed=23186163; DOI=10.1021/pr300630k;
RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA Mohammed S.;
RT "Toward a comprehensive characterization of a human cancer cell
RT phosphoproteome.";
RL J. Proteome Res. 12:260-271(2013).
RN [12]
RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC TISSUE=Colon carcinoma;
RX PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA Bedford M.T., Comb M.J.;
RT "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT methylation.";
RL Mol. Cell. Proteomics 13:372-387(2014).
RN [13]
RP STRUCTURE BY NMR OF 24-90, SUBUNIT, AND DOMAIN N-TERMINAL.
RX PubMed=20732328; DOI=10.1016/j.jmb.2010.08.025;
RA Laird K.M., Briggs L.L., Boss J.M., Summers M.F., Garvie C.W.;
RT "Solution structure of the heterotrimeric complex between the interaction
RT domains of RFX5 and RFXAP from the RFX gene regulatory complex.";
RL J. Mol. Biol. 403:40-51(2010).
RN [14]
RP X-RAY CRYSTALLOGRAPHY (1.57 ANGSTROMS) OF 167-183 IN COMPLEX WITH RFXANK,
RP AND MOTIF.
RX PubMed=22649097; DOI=10.1126/scisignal.2002979;
RA Xu C., Jin J., Bian C., Lam R., Tian R., Weist R., You L., Nie J.,
RA Bochkarev A., Tempel W., Tan C.S., Wasney G.A., Vedadi M., Gish G.D.,
RA Arrowsmith C.H., Pawson T., Yang X.J., Min J.;
RT "Sequence-specific recognition of a PxLPxI/L motif by an ankyrin repeat
RT tumbler lock.";
RL Sci. Signal. 5:RA39-RA39(2012).
RN [15]
RP VARIANT BLS2 GLN-149.
RX PubMed=10825209; DOI=10.1128/mcb.20.12.4455-4461.2000;
RA Nekrep N., Jabrane-Ferrat N., Peterlin B.M.;
RT "Mutations in the bare lymphocyte syndrome define critical steps in the
RT assembly of the regulatory factor X complex.";
RL Mol. Cell. Biol. 20:4455-4461(2000).
CC -!- FUNCTION: Activates transcription from class II MHC promoters.
CC Recognizes X-boxes. Mediates cooperative binding between RFX and NF-Y.
CC RFX binds the X1 box of MHC-II promoters.
CC -!- SUBUNIT: Homodimer. The RFX heterotetrameric complex consists of 2
CC molecules of RFX5 and one each of RFXAP and RFX-B/RFXANK; with each
CC subunit representing a separate complementation group. Interacts (via
CC PxLPxI/L motif) with RFXANK (via ankyrin repeats); the interaction is
CC direct. RFX forms cooperative DNA binding complexes with X2BP and
CC CBF/NF-Y. RFX associates with CIITA to form an active transcriptional
CC complex. {ECO:0000269|PubMed:20732328, ECO:0000269|PubMed:22649097}.
CC -!- INTERACTION:
CC P48382; P33076: CIITA; NbExp=2; IntAct=EBI-923266, EBI-1538819;
CC P48382; Q92769: HDAC2; NbExp=4; IntAct=EBI-923266, EBI-301821;
CC P48382; O14593: RFXANK; NbExp=8; IntAct=EBI-923266, EBI-1057665;
CC P48382; O00287: RFXAP; NbExp=11; IntAct=EBI-923266, EBI-3929296;
CC -!- SUBCELLULAR LOCATION: Nucleus.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1;
CC IsoId=P48382-1; Sequence=Displayed;
CC Name=2;
CC IsoId=P48382-2; Sequence=VSP_055864;
CC -!- TISSUE SPECIFICITY: Ubiquitous.
CC -!- DOMAIN: The N-terminus is required for dimer formation, association
CC with RFXANK and RFXAP, assembly of the RFX complex, and for binding of
CC this complex to its X box target site in the MHC-II promoter. The C-
CC terminus mediates cooperative binding between the RFX complex and NF-Y.
CC {ECO:0000269|PubMed:20732328}.
CC -!- DOMAIN: The PxLPxI/L motif mediates interaction with ankyrin repeats of
CC RFXANK. {ECO:0000269|PubMed:22649097}.
CC -!- PTM: Phosphorylated.
CC -!- DISEASE: Bare lymphocyte syndrome 2 (BLS2) [MIM:209920]: A severe
CC combined immunodeficiency disease with early onset. It is characterized
CC by a profound defect in constitutive and interferon-gamma induced MHC
CC II expression, absence of cellular and humoral T-cell response to
CC antigen challenge, hypogammaglobulinemia and impaired antibody
CC production. The consequence include extreme susceptibility to viral,
CC bacterial and fungal infections. {ECO:0000269|PubMed:10825209}.
CC Note=The disease is caused by variants affecting the gene represented
CC in this entry.
CC -!- SIMILARITY: Belongs to the RFX family. {ECO:0000255|PROSITE-
CC ProRule:PRU00858}.
CC -!- WEB RESOURCE: Name=RFX5base; Note=RFX5 mutation db;
CC URL="http://structure.bmc.lu.se/idbase/RFX5base/";
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; X85786; CAA59771.1; -; mRNA.
DR EMBL; AK302891; BAH13834.1; -; mRNA.
DR EMBL; AL391069; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; CH471121; EAW53446.1; -; Genomic_DNA.
DR EMBL; CH471121; EAW53447.1; -; Genomic_DNA.
DR EMBL; CH471121; EAW53448.1; -; Genomic_DNA.
DR EMBL; BC017471; AAH17471.1; -; mRNA.
DR CCDS; CCDS994.1; -. [P48382-1]
DR PIR; I38155; I38155.
DR RefSeq; NP_000440.1; NM_000449.3. [P48382-1]
DR RefSeq; NP_001020774.1; NM_001025603.1. [P48382-1]
DR RefSeq; XP_005245462.1; XM_005245405.1.
DR RefSeq; XP_005245463.1; XM_005245406.3.
DR RefSeq; XP_011508149.1; XM_011509847.1.
DR RefSeq; XP_011508150.1; XM_011509848.1.
DR RefSeq; XP_011508151.1; XM_011509849.1.
DR RefSeq; XP_011508152.1; XM_011509850.1.
DR PDB; 2KW3; NMR; -; A/B=24-90.
DR PDB; 3V30; X-ray; 1.57 A; B=167-183.
DR PDBsum; 2KW3; -.
DR PDBsum; 3V30; -.
DR AlphaFoldDB; P48382; -.
DR SMR; P48382; -.
DR BioGRID; 111925; 42.
DR ComplexPortal; CPX-6461; RFX gene regulatory complex.
DR CORUM; P48382; -.
DR ELM; P48382; -.
DR IntAct; P48382; 22.
DR MINT; P48382; -.
DR STRING; 9606.ENSP00000290524; -.
DR GlyGen; P48382; 2 sites, 1 O-linked glycan (2 sites).
DR iPTMnet; P48382; -.
DR MetOSite; P48382; -.
DR PhosphoSitePlus; P48382; -.
DR BioMuta; RFX5; -.
DR DMDM; 1350587; -.
DR EPD; P48382; -.
DR jPOST; P48382; -.
DR MassIVE; P48382; -.
DR MaxQB; P48382; -.
DR PaxDb; P48382; -.
DR PeptideAtlas; P48382; -.
DR PRIDE; P48382; -.
DR ProteomicsDB; 55886; -. [P48382-1]
DR ProteomicsDB; 6925; -.
DR Antibodypedia; 683; 299 antibodies from 34 providers.
DR DNASU; 5993; -.
DR Ensembl; ENST00000290524.8; ENSP00000290524.4; ENSG00000143390.18. [P48382-1]
DR Ensembl; ENST00000368870.6; ENSP00000357864.2; ENSG00000143390.18. [P48382-1]
DR Ensembl; ENST00000452671.7; ENSP00000389130.2; ENSG00000143390.18. [P48382-1]
DR GeneID; 5993; -.
DR KEGG; hsa:5993; -.
DR MANE-Select; ENST00000452671.7; ENSP00000389130.2; NM_001025603.2; NP_001020774.1.
DR UCSC; uc001exv.2; human. [P48382-1]
DR CTD; 5993; -.
DR DisGeNET; 5993; -.
DR GeneCards; RFX5; -.
DR HGNC; HGNC:9986; RFX5.
DR HPA; ENSG00000143390; Low tissue specificity.
DR MalaCards; RFX5; -.
DR MIM; 209920; phenotype.
DR MIM; 601863; gene.
DR neXtProt; NX_P48382; -.
DR OpenTargets; ENSG00000143390; -.
DR Orphanet; 572; Immunodeficiency by defective expression of MHC class II.
DR PharmGKB; PA34356; -.
DR VEuPathDB; HostDB:ENSG00000143390; -.
DR eggNOG; KOG3712; Eukaryota.
DR GeneTree; ENSGT01050000244970; -.
DR InParanoid; P48382; -.
DR OMA; INMILPA; -.
DR OrthoDB; 67697at2759; -.
DR PhylomeDB; P48382; -.
DR TreeFam; TF321340; -.
DR PathwayCommons; P48382; -.
DR SignaLink; P48382; -.
DR SIGNOR; P48382; -.
DR BioGRID-ORCS; 5993; 38 hits in 1102 CRISPR screens.
DR ChiTaRS; RFX5; human.
DR EvolutionaryTrace; P48382; -.
DR GeneWiki; RFX5; -.
DR GenomeRNAi; 5993; -.
DR Pharos; P48382; Tbio.
DR PRO; PR:P48382; -.
DR Proteomes; UP000005640; Chromosome 1.
DR RNAct; P48382; protein.
DR Bgee; ENSG00000143390; Expressed in epithelium of nasopharynx and 200 other tissues.
DR ExpressionAtlas; P48382; baseline and differential.
DR Genevisible; P48382; HS.
DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR GO; GO:0005634; C:nucleus; IDA:ComplexPortal.
DR GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IPI:ARUK-UCL.
DR GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:GO_Central.
DR GO; GO:0043565; F:sequence-specific DNA binding; IDA:NTNU_SB.
DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR GO; GO:0045348; P:positive regulation of MHC class II biosynthetic process; IC:ComplexPortal.
DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR Gene3D; 1.10.10.10; -; 1.
DR IDEAL; IID00452; -.
DR InterPro; IPR003150; DNA-bd_RFX.
DR InterPro; IPR039779; RFX-like.
DR InterPro; IPR033486; RFX5.
DR InterPro; IPR029298; RFX5_C.
DR InterPro; IPR040889; RFX5_N.
DR InterPro; IPR036388; WH-like_DNA-bd_sf.
DR InterPro; IPR036390; WH_DNA-bd_sf.
DR PANTHER; PTHR12619; PTHR12619; 1.
DR PANTHER; PTHR12619:SF18; PTHR12619:SF18; 1.
DR Pfam; PF14621; RFX5_DNA_bdg; 1.
DR Pfam; PF18326; RFX5_N; 1.
DR Pfam; PF02257; RFX_DNA_binding; 1.
DR SMART; SM01306; RFX5_DNA_bdg; 1.
DR SUPFAM; SSF46785; SSF46785; 1.
DR PROSITE; PS51526; RFX_DBD; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Acetylation; Activator; Alternative splicing;
KW Direct protein sequencing; Disease variant; DNA-binding; Nucleus;
KW Phosphoprotein; Reference proteome; SCID; Transcription;
KW Transcription regulation.
FT INIT_MET 1
FT /note="Removed"
FT /evidence="ECO:0007744|PubMed:22814378"
FT CHAIN 2..616
FT /note="DNA-binding protein RFX5"
FT /id="PRO_0000215292"
FT DNA_BIND 92..168
FT /note="RFX-type winged-helix"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00858"
FT REGION 1..29
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 25..90
FT /note="N-terminal domain"
FT REGION 62..66
FT /note="Leucine-rich region; critical for dimer formation
FT and for interaction with RFXAP"
FT REGION 252..314
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 391..616
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOTIF 173..178
FT /note="PxLPxI/L motif; mediates interaction with RFXANK"
FT /evidence="ECO:0000269|PubMed:22649097"
FT COMPBIAS 252..289
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 420..434
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 476..501
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT MOD_RES 2
FT /note="N-acetylalanine"
FT /evidence="ECO:0007744|PubMed:22814378"
FT MOD_RES 10
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:23186163"
FT MOD_RES 185
FT /note="Phosphoserine"
FT /evidence="ECO:0007744|PubMed:20068231"
FT VAR_SEQ 78..117
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000303|PubMed:14702039"
FT /id="VSP_055864"
FT VARIANT 149
FT /note="R -> Q (in BLS2; dbSNP:rs137853099)"
FT /evidence="ECO:0000269|PubMed:10825209"
FT /id="VAR_015550"
FT VARIANT 197
FT /note="R -> Q (in dbSNP:rs2233851)"
FT /id="VAR_034448"
FT VARIANT 409
FT /note="P -> R (in dbSNP:rs2233854)"
FT /id="VAR_034449"
FT VARIANT 499
FT /note="P -> S (in dbSNP:rs2233855)"
FT /id="VAR_034450"
FT HELIX 30..36
FT /evidence="ECO:0007829|PDB:2KW3"
FT HELIX 40..54
FT /evidence="ECO:0007829|PDB:2KW3"
FT HELIX 58..66
FT /evidence="ECO:0007829|PDB:2KW3"
FT HELIX 74..78
FT /evidence="ECO:0007829|PDB:2KW3"
FT STRAND 82..86
FT /evidence="ECO:0007829|PDB:2KW3"
FT STRAND 178..180
FT /evidence="ECO:0007829|PDB:3V30"
SQ SEQUENCE 616 AA; 65323 MW; 5EBB33C677BB717F CRC64;
MAEDEPDAKS PKTGGRAPPG GAEAGEPTTL LQRLRGTISK AVQNKVEGIL QDVQKFSDND
KLYLYLQLPS GPTTGDKSSE PSTLSNEEYM YAYRWIRNHL EEHTDTCLPK QSVYDAYRKY
CESLACCRPL STANFGKIIR EIFPDIKARR LGGRGQSKYC YSGIRRKTLV SMPPLPGLDL
KGSESPEMGP EVTPAPRDEL VEAACALTCD WAERILKRSF SSIVEVARFL LQQHLISARS
AHAHVLKAMG LAEEDEHAPR ERSSKPKNGL ENPEGGAHKK PERLAQPPKD LEARTGAGPL
ARGERKKSVV ESSAPGANNL QVNALVARLP LLLPRAPRSL IPPIPVSPPI LAPRLSSGAL
KVATLPLSSR AGAPPAAVPI INMILPTVPA LPGPGPGPGR APPGGLTQPR GTENREVGIG
GDQGPHDKGV KRTAEVPVSE ASGQAPPAKA AKQDIEDTAS DAKRKRGRPR KKSGGSGERN
STPLKSAAAM ESAQSSRLPW ETWGSGGEGN SAGGAERPGP MGEAEKGAVL AQGQGDGTVS
KGGRGPGSQH TKEAEDKIPL VPSKVSVIKG SRSQKEAFPL AKGEVDTAPQ GNKDLKEHVL
QSSLSQEHKD PKATPP
